Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 5 58-5, 2005, Pages

  Chen, YingJie ^a,c   Li, Yunfang ^a   Zhang, Ping ^a   Traverse, Jay H ^a   Hou, Mingxiao ^a   Xu, Xin ^a   Kimoto, Masumi ^b   Bache, Robert J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b OKAYAMA PREFECTURAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Exercise; Heart failure; Nitric oxide; Pacemaker

Indexed keywords

ACETYLCHOLINE; CAVEOLIN 1; COMPLEMENTARY DNA; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN ARGININE METHYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREADMILL EXERCISE; VASODILATATION;

AMIDOHYDROLASES; ANIMALS; ARGININE; BLOTTING, WESTERN; CYTOCHROMES C; DOGS; ENDOTHELIUM, VASCULAR; EXERTION; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MYOCARDIUM; OXYGEN CONSUMPTION; REST; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBCELLULAR FRACTIONS; VASODILATION;

EID: 27144436415     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00224.2005     Document Type: Article

References (34)

1. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, and Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydorlase. Arterioscler Thromb Vasc Biol 23: 1455-1459, 2003.
2. Arrigoni FI, Vallance P, Haworth SG, and Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107: 1195-1201, 2003.
3. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, and Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100: 292-298, 1999.
4. Birdsey GM, Leiper JM, and Vallance P. Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line. Acta Physiol Scand 168: 773-792, 2000.
5. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, and Sessa WC. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6: 1362-1367, 2000.
6. Chen Y, Traverse JH, Du R, Hou M, and Bache RJ. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 106: 273-279, 2002.
7. Chen Y, Park S, Li Y, Missov E, Hou M, Han X, Hall JL, Miller LW, and Bache RJ. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics 14: 251-260, 2003.
8. + carrier hCAT-2B. Nitric Oxide 1: 65-73, 1997.
9. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, and Arnold JM. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 37: 667-675, 1998.
10. García-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li SW, Lisanti MP, and Sessa WC. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin-functional significance of the NOS caveolin binding domain in vivo. J Biol Chem 272: 25437-25440, 1997.
11. Gorenflo M, Zheng C, Werle E, Fiehn W, and Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37: 489-492, 2001.
12. Hirooka Y, Imaizumi T, Tagawa T, Shiramoto M, Endo T, Ando S, and Takeshita A. Effects of L-arginine on impaired acetycholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 90: 658-668, 1994.
13. Hare JM, Lofthouse RA, Juang GJ, Colman L, Ricker KM, Kim B, Senzaki H, Cao S, Tunin RS, and Kass DA. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. Circ Res 86: 1085-1092, 2000.
14. G-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 117: 237-238, 1995.
15. Komaru T, Lamping KG, Eastham CL, Harrison DG, Marcus ML, and Dellsperger KC. Effect of an arginine analogue on acetylcholine-induced coronary microvascular dilatation in dogs. Am J Physiol Heart Circ Physiol 261: H2001-H2007, 1991.
16. Kubo SH, Rector TS, Bank AJ, Williams RE, and Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 84: 1589-1596, 1991.
17. Laussmann T, Janosi RA, Fingas CD, Schlieper GR, Schlack W, Schrader J, and Decking UK. Myocardial proteome analysis reveals reduced NOS inhibition and enhanced glycolytic capacity in areas of low local blood flow. FASEB J 16: 628-630, 2002.
18. Leiper J, Murray-Rust J, McDonald N, and Vallance P. s-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 99: 13527-13532, 2002.
19. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, and Vallance P. Identification of two human dimethylarginine dimethlaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem 343: 209-214, 1999.
20. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, and Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106: 987-992, 2002.
21. Masuda H, Goto M, Tamaoki S, and Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 126: 211-218, 1999.
22. 2+-calmodulin and caveolin. J Biol Chem 272: 15583-15586, 2000.
23. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, and Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99: 1141-1146, 1999.
24. G-dimethylarginine dimethylaminohydrolase from rat kidney. J Biol Chem 264: 10205-10209, 1989.
25. Ohnishi M, Wada A, Tsutamoto T, Fujii M, Matsumoto T, Yamamoto T, Takayama T, Wang X, and Kinoshita M. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci 103, Suppl 48: S241-S244, 2002.
26. Prior DL, Jennings GLR, and Chin-Dusting JP. Transient improvement of acetylcholine responses after short-term oral L-arginine in forearms of human heart failure. J Cardiovasc Pharmacol 36: 31-37, 2000.
27. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, and Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83: 969-979, 1998.
28. Stein B, Eschenhagen T, Rudiger J, Scholz H, Forstermann U, and Gath I. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. J Am Coll Cardiol 32: 1179-1186, 1998.
29. Tang J, Kao PN, and Herschman HR. Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3. J Biol Chem 275: 19866-19876, 2000.
30. Traverse JH, Chen Y, Crampton M, Voss S, and Bache RJ. Increased extravascular forces limit endothelium-dependent and -independent coronary vasodilation in congestive heart failure. Cardiovasc Res 52: 454-461, 2001.
31. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, and Imaizumi T. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 92: 226-233, 2003.
32. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, and Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62: 2425-2430, 1998.
33. Wang J, Seyedi N, Xu XB, Wolin MS, and Hintze TH. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol Heart Circ Physiol 266: H670-H680, 1994.
34. Zhao G, Shen W, Zhang X, Smith CJ, and Hintze TH. Loss of nitric oxide production in the coronary circulation after the development of dilated cardiomyopathy: a specific defect in the neural regulation of coronary blood flow. Clin Exp Pharmacol Physiol 23: 715-721, 1996.